The current role of prostatic acid phosphatase and prostate-specific antigen in the management of prostate cancer.
Although PSA is considered to be the true serum marker of prostatic tissue and a valuable indicator for cancer in the gland, knowledge of its significance and limitations is essential to its use for screening, staging, and monitoring CAP. PSA may be used in conjunction with DRE for early detection of CAP. Men with abnormal DRE should have a TRUS with or without biopsy. In men older than 50 years and with negative DRE and PSA < 4 ng/mL, annual evaluations are prudent. In patients with a PSA range of 4.0 to 9.9 ng/mL, high-risk groups such as black males and those with a positive family history should have TRUS. Males with negative DRE in the PSA range of 4.0 to 9.9 ng/mL should have TRUS to evaluate prostate volume and PSAD. Biopsy should be considered in those with PSAD > 0.15. Men with PSA > 10 ng/mL, even in the presence of an enlarged benign prostate, should have multiple directed biopsies under TRUS guidance.
Shetty
S D
SD
Department of Urology, Henry Ford Hospital, Detroit, MI 48202.
Cerny
J C
JC
D000135:Acid Phosphatase / Q000097:blood* / Q000737:chemistry; D014408:Biomarkers, Tumor / Q000097:blood* / Q000737:chemistry; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000737:chemistry; D011470:Prostatic Hyperplasia / Q000097:blood / Q000453:epidemiology; D011471:Prostatic Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000473:pathology; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen